DS-1001b

• Description:

  DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity[1][2][3].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Isocitrate Dehydrogenase (IDH)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ds-1001b.html

• Purity:

  99.71

• Solubility:

  DMSO : 29 mg/mL (ultrasonic)

• Smiles:

  CC(C)(N)C.O=C(N1C2=CC=CC(/C=C/C(O)=O)=C2C(C)=C1)C3=C(C(C)(F)C)ON=C3C4=C(C=C(Cl)C=C4Cl)Cl

• Molecular Formula:

  C29H29Cl3FN3O4

• Molecular Weight:

  608.92

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Zhao Yizhaiteng, et al. Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor. WO2016052697A1.|[2]Nakagawa M, et al. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Oncogene. 2019 Oct;38 (42) :6835-6849.|[3]Matsunaga H, et al. Characterization of a novel BBB-permeable mutant IDH1 inhibitor, DS-1001b. Annals of Oncology, 2019, 30: v145-v146.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  1898207-64-1